Xtrackers RREEF全球自然资源主动型ETF NRES 深 沪
已收盘 07-02 16:00:00 美东时间
31.0659
+0.510
+1.67%
华盛通- 最 高31.0659
- 今 开30.85
- 成交量 14股
- 最 低 31.0659
- 昨 收 30.5561
- 总市值 3246.39万
- 52周最高 35.2542
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 24.3191
- 委 比 20.00%
- 总股本 104.50万
- 历史最高 35.2542
- 量 比 0
- 振 幅 0.00%
- 历史最低 20.5126
- 每 手 1
- 风险率 3.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多WRAPUP 3-Iran reasserts its right to control shipping in Strait of Hormuz after ship hit near Oman
WRAPUP 3-Iran reasserts its right to control shipping in Strait of Hormuz after ship hit near Oman Adds U.S. official in paragraph 5, fertiliser shipments in paragraph 8, Israel dropping leaflets again in southern Lebanon and Lebanon context in paragraphs 22-24 Iran says its rights in Strait of Horm
06-26 18:42
BRIEF-Regeneron Provides Update On Phase 3 Trial Of Fianlimab (Lag-3 Inhibitor) Combination In First-Line Unresectable Or Metastatic Melanoma
BRIEF-Regeneron Provides Update On Phase 3 Trial Of Fianlimab (Lag-3 Inhibitor) Combination In First-Line Unresectable Or Metastatic Melanoma May 16 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : REGENERON PROVIDES UPDATE ON PHASE 3 TRIAL OF FIANLIMAB (LAG-3 INHIBITOR) COMBINATION IN FIRST-LINE
05-16 08:24
BRIEF-Immunitybio Announces Nccn® Clinical Practice Guidelines In Oncology Have Been Updated To Include Anktiva® Plus Bcg For Patients With Bcg-Unresponsive Nmibc With Papillary-Only Disease
BRIEF-Immunitybio Announces Nccn® Clinical Practice Guidelines In Oncology Have Been Updated To Include Anktiva® Plus Bcg For Patients With Bcg-Unresponsive Nmibc With Papillary-Only Disease March 17 (Reuters) - Immunitybio Inc IBRX.O : IMMUNITYBIO ANNOUNCES NCCN® CLINICAL PRACTICE GUIDELINES IN ONC
03-17 19:40
BRIEF-TARA-002 Demonstrates 68% Complete Response Rate At Six Months In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
BRIEF-TARA-002 Demonstrates 68% Complete Response Rate At Six Months In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Feb 23 (Reuters) - Protara Therapeutics Inc TARA.O : TARA-002 DEMONSTRATES 68% COMPLETE RESPONSE RATE AT SIX MONTHS IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER PROTA
02-24 06:28
Zelenskiy seeks meeting with Trump to hammer out issue of territory
Ukraine, US near finalising 20-point framework to end war Territorial issues remain unresolved, require leaders' meeting US, Ukraine discuss security guarantees, economic recovery plans By Olena Harma...
2025-12-24 17:36
BRIEF-Anktiva® With Bcg Demonstrates 96% Survival From Bladder Cancer
Dec 16 (Reuters) - Immunitybio Inc IBRX.O: ANKTIVA® WITH BCG DEMONSTRATES 96% SURVIVAL FROM BLADDER CANCER AT THREE YEARS WITH MEDIAN SURVIVAL NOT YET REACHED IN BCG-UNRESPONSIVE HIGH-GRADE PAPILLARY-...
2025-12-16 22:10
BRIEF-BetaGlue Therapeutics Says MHRA Approves Clinical Trial Application For YntraDose In uLA-PDAC
Nov 12 (Reuters) - BetaGlue Therapeutics: BETAGLUE THERAPEUTICS: MHRA APPROVED CLINICAL TRIAL APPLICATION FOR YNTRADOSE IN UNRESECTABLE LOCALLY ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA ((Reuters.Brie...
2025-11-13 02:30
BRIEF-Spelman College Receives $38 Mln Unrestricted Gift From Mackenzie Scott
Nov 3 (Reuters) - SPELMAN COLLEGE: SPELMAN COLLEGE:RECEIVES $38 MILLION UNRESTRICTED GIFT FROM PHILANTHROPIST MACKENZIE SCOTT Source text: ID:nGNXc4YDqB ((((Reuters.Briefs@thomsonreuters.com));))
2025-11-04 00:40
BRIEF-Arcus Bioscience Announces First Overall Survival Results From Phase 2 Edge-Gastric Study
Oct 12 (Reuters) - Arcus Biosciences Inc RCUS.N: ANTI-TIGIT DOMVANALIMAB PLUS ANTI-PD-1 ZIMBERELIMAB AND CHEMOTHERAPY SHOWED 26.7 MONTHS OF MEDIAN OVERALL SURVIVAL AS FIRST-LINE TREATMENT OF UNRESECTA...
2025-10-13 06:10
BRIEF-UAW Faction Seeks To Oust President Fain In Sign Of Union Unrest - Bloomberg News
Aug 5 (Reuters) - UAW FACTION SEEKS TO OUST PRESIDENT FAIN IN SIGN OF UNION UNREST - BLOOMBERG NEWS WORKERS AT STELLANTIS TRUCK FACTORY IN DETROIT, ENGINE PLANT IN MICHIGAN VOTED OVER WEEKEND TO START...
2025-08-05 22:06
